Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib for Pediatric NTRK-Fusion High-Grade Glioma
2023-508953-16-00Phase 2Authorised
- Sponsor
- Nationwide Children's Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of larotrectinib in high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG), sponsored by Nationwide Children's Hospital. Primary endpoints: Disease control rate at end of cycle 2 and Treatment-related adverse events. Planned start May 2024; status: authorised.
02
Drugs
larotrectinib
03
Conditions
high-grade glioma (HGG)diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on 2023-508953-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508953-16-00.